Anticipating trends, addressing challenges, and providing solutions that enable CDMOs to adapt to market changes.
-New service ensures rapid delivery of small volume clinical trial materials, solving a critical bottleneck in drug development- SPOKANE, Wash.–(BUSINESS WIRE)–February 12, 2025– Selkirk Pharma, Inc., ...
In July 2025 Symbiosis manufactured its 1,000th sterile batch, marking over 14 years of support for biopharma clients.
Taiwan-based Bora Pharmaceuticals plans to add further sterile fill/finish capacity at its facility in Baltimore, MD. Installation of a new AST GENiSYS ® C automated vial, syringe, and cartridge line ...
ST. LOUIS--(BUSINESS WIRE)--Kindeva Drug Delivery (Kindeva), a leading global CDMO, today announced two key milestones for its state-of-the-art Bridgeton, MO, facility. The site has successfully ...
Jubilant HollisterStier invests $300 million to double sterile injectable manufacturing capacity in the US, accelerated by ...
New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte’s Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates ...
New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte’s Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates ...
Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback